LOS ANGELES--(BUSINESS WIRE)--ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy. Metformin therapy is a currently used therapeutic option for Type 2 diabetes mellitus in overweight or obese patients.
